Condition: Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia · Acute Myeloid Leukemia · Sponsor: Clinical Hub for Interventional Research (CHOIR)
The goal of this project is to see if two new potential treatments (defactinib and the combination tablet of decitabine/cedazuridine) can safely be combined to improve outcomes in people with high-risk myelodysplastic syndrome (MDS), certain forms of Acute Myeloid Leukaemia (AML), and Chronic Myelomonocytic Leukaemia (CMML). Decitabine/cedazuridine is approved for use by the Australian Therapeutics Goods Administration (TGA) as treatment for MDS. Defactinib is an experimental treatment. This means it is not an approved treatment for MDS in Australia. So far it has been given to over 625 patients in studies across the world. All study participants will receive active treatment, there is no placebo. Participants will take the decitabine/cedazuridine treatment once a day for 5 days in a row (day 1 to day 5) on its own for the first month (cycle). From month 2 participants will take the decitabine/cedazuridine treatment and will also take the defactinib treatment, both for 5 days in a row on days 1 to day 5 each month (cycle). Defactinib is taken twice a day.
This description comes directly from the study's public registry record.
John Pimanda, Professor · 1234567 · celestial.jcsmr@anu.edu.au
Mark Polizzotto, Professor · celestial.jcsmr@anu.edu.au
Always discuss trial participation with your own doctor first.
| Prince of Wales Hospital | Sydney, New South Wales, Australia | Recruiting |
| Royal Prince Alfred Hospital | Sydney, New South Wales, Australia | Recruiting |
| Concord Repatriation and General Hospital | Sydney, New South Wales, Australia | Recruiting |
| Nepean Hospital | Sydney, New South Wales, Australia | Recruiting |
| Westmead Hospital | Westmead, New South Wales, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05636514